IMIC(000516) 东海证券·2025-04-25 12:23Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company has shown a continuous narrowing of losses, with revenue for 2024 reaching 4.815 billion yuan, a year-on-year increase of 4.28%. The net loss attributable to the parent company was 254.13 million yuan, a reduction of 31.0% year-on-year [2][6] - The company is actively expanding its non-medical insurance business while maintaining a stable operational performance and optimizing its revenue structure [6] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 4.815 billion yuan, with a year-on-year growth of 4.28%. The net loss attributable to the parent company was 254.13 million yuan, which is a 31.0% reduction compared to the previous year [2][3] - For Q1 2025, the company reported a revenue of 999.7 million yuan, a decrease of 15.0% year-on-year, primarily due to DRG cost control and last year's high base effect. The net loss attributable to the parent company was 106 million yuan, a decrease of 1.4% year-on-year [2] Operational Highlights - The company’s high-tech hospital generated a revenue of 1.525 billion yuan in 2024, with a net profit of 85 million yuan, reflecting a year-on-year increase of 2.7% and 21.6% respectively. The hospital is operating at full capacity, with key medical quality indicators steadily improving [6] - The central hospital achieved a revenue of 3.274 billion yuan in 2024, a year-on-year increase of 7.6%, while the net loss was reduced by 36.7% to 165 million yuan. The hospital's outpatient and emergency service volume reached 1.4182 million visits, a year-on-year increase of 18.9% [6] Future Outlook - The company is expected to continue its development of a comprehensive medical innovation business model that combines serious medical care with consumer medical services. The revenue structure is anticipated to improve as the volume of medical services increases [6] - The profit forecasts for 2025 and 2026 have been adjusted to reflect the impact of medical insurance cost control policies, with projected net losses of 137 million yuan and 80 million yuan respectively, before turning profitable in 2027 with a net profit of 133 million yuan [6][7]